GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin...

GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in
Sirtuin Research and Development

LONDON, PHILADELPHIA and CAMBRIDGE, Mass., June 6 /PRNewswire-FirstCall/
-- GlaxoSmithKline (NYSE: GSK) announced today that it has completed its
acquisition of Sirtris Pharmaceuticals, Inc. (Sirtris) for approximately
USD720 million (or approx. GBP362 million) through a cash tender offer and
merger of USD22.50 (or approx. GBP11.33) per share.
Through the acquisition of Sirtris, GSK has significantly enhanced its
metabolic, neurology, immunology and inflammation research efforts by
establishing a presence in the field of sirtuins, a recently discovered class
of enzymes that is believed to be involved in the ageing process.
Sirtris will become part of GSK's Drug Discovery organization, while
continuing to operate from laboratories in Cambridge, Massachusetts, as an
autonomous drug discovery unit. Christoph Westphal, CEO and Vice Chair of
Sirtris, and the management team will continue to lead this autonomous unit.
About GSK
GSK -- one of the world's leading research-based pharmaceutical and
healthcare companies -- is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For company
information including a copy of this announcement and details of the company's
updated product development pipeline, visit GSK at www.gsk.com.
SOURCE GlaxoSmithKline

UK Media enquiries: Philip Thomson, Claire Brough, Alice Hunt, or Gwenan
White, 020-8047-5502; or US Media enquiries: Nancy Pekarek, +1-215-751-7709,
or Mary Anne Rhyne, +1-919-483-2839, or Melinda Stubbee, +1-610-270-6247, or
European Analyst, Investor enquiries: David Mawdsley, 020-8047-5564, Sally
Ferguson, 020-8047-5543, or Gary Davies, 020-8047-5503, or US Analyst,
Investor enquiries: Frank Murdolo, +1-215-751-7002, or Tom Curry,
+1-215-751-5419, all of GlaxoSmithKline